| 1 |
Collins R,Armitage J,Parish S, et al. Heart Protection Study Col-laborative G. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a ran-domised placebo-controlled trial[J]. Lancet, 2003, 361(9374): 2005-2016.
|
| 2 |
Graham I,Atar D,Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiolo-gy and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)[J]. Eur J Cardiovasc Prev Rehabil, 2007, 14(Suppl 2): S1-113.
|
| 3 |
Catapano AL,Reiner Z,De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiol-ogy (ESC) and the European Atherosclerosis Society (EAS)[J]. Atherosclerosis, 2011, 217(1): 3-46.
|
| 4 |
Rubins HB,Robins SJ,Collins D, et al. Gemfibrozil for the sec-ondary prevention of coronary heart disease in men with low lev-els of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group[J]. N Engl J Med, 1999, 341(6): 410-418.
|
| 5 |
Messerli FH,Bangalore S,Ram VS. Telmisartan, ramipril, or both in patients at high risk of vascular events[J]. N Engl J Med, 2008, 359: 426-427.
|
| 6 |
Hirsch AT,Haskal ZJ,Hertzer NR, et al. ACC/AHA 2005 Prac-tice Guidelines for the management of patients with peripheral ar-terial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardio-vascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Com-mittee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American As-sociation of Cardiovascular and Pulmonary Rehabilitation; Nation-al Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation[J]. Circulation, 2006, 113(11): e463-e654.
|
| 7 |
Mancia G,Laurent S,Agabiti-Rosei E, et al. Reappraisal of Eu-ropean guidelines on hypertension management: a European Soci-ety of Hypertension Task Force document[J]. J Hypertens, 2009, 27(11): 2121-2158.
|
| 8 |
Yusuf S,Sleight P,Pogue J, et al. Effects of an angiotensin-con-verting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators[J]. N Engl J Med, 2000, 342(3): 145-153.
|
| 9 |
Hoeks SE,Poldermans D. European Society of Cardiology 2009 guidelines for preoperative cardiac risk assessment and periopera-tive cardiac management in noncardiac surgery: key messages for clinical practice[J]. Pol Arch Med Wewn, 2010, 120(7-8): 294-299.
|
| 10 |
Zisser H,Gong P,Kelley CM, et al. Exercise and diabetes[J]. Int J Clin Pract Suppl, 2011, 170: 71-75.
|
| 11 |
American Diabetes Association. Standards of medical care for pa-tients with diabetes mellitus[J]. Diabetes Care, 2003, 26: S33-S50.
|
| 12 |
Donohoe ME,Fletton JA,Hook A, et al. Improving foot care for people with diabetes mellitus—a randomized controlled trial of an integrated care approach[J]. Diabet Med, 2000, 17(8): 581-587.
|
| 13 |
Fowler B,Jamrozik K,Norman P, et al. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers[J]. Aust N Z J Public Health, 2002, 26(3): 219-224.
|
| 14 |
Hobbs SD,Bradbury AW. Smoking cessation strategies in pa-tients with peripheral arterial disease: an evidence-based ap-proach[J]. Eur J Vasc Endovasc Surg, 2003, 26(4): 341-347.
|
| 15 |
Hennrikus D,Joseph AM,Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial[J]. J Am Coll Cardiol, 2010, 56(25): 2105-2112.
|
| 16 |
Knight C,Howard P,Baker CL, et al. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model[J]. Value Health, 2010, 13(2): 209-214.
|
| 17 |
Jorenby DE,Leischow SJ,Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smok-ing cessation[J].N Engl J Med, 1999, 340(9): 685-691.
|
| 18 |
Antithrombotic Trialists' (ATT) Collaboration,Baigent C,Black-well L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual partic-ipant data from randomised trials[J]. Lancet, 2009, 373(9678): 1849-1860.
|
| 19 |
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee[J]. Lancet, 1996, 348(9038): 1329-1339.
|
| 20 |
Bhatt DL,Fox KA,Hacke W, et al. Clopidogrel and aspirin ver-sus aspirin alone for the prevention of atherothrombotic events[J]. N Engl J Med, 2006, 354(16): 1706-1717.
|
| 21 |
Cacoub PP,Bhatt DL,Steg PG, et al. Patients with peripheral ar-terial disease in the CHARISMA trial[J]. Eur Heart J, 2009, 30(2): 192-201.
|
| 22 |
Bendermacher BL,Willigendael EM,Teijink JA, et al. Super-vised exercise therapy versus non-supervised exercise therapy for intermittent claudication[J]. Cochrane Database Syst Rev, 2006: CD005263.
|
| 23 |
Watson L,Ellis B,Leng GC. Exercise for intermittent claudica-tion[J]. Cochrane Database Syst Rev, 2008: CD000990.
|
| 24 |
Hiatt WR,Wolfel EE,Meier RH, et al. Superiority of treadmill walking exercise versus strength training for patients with periph-eral arterial disease. Implications for the mechanism of the train-ing response[J]. Circulation, 1994, 90(4): 1866-1874.
|
| 25 |
Roddy SP,Abdelnoor M,Stranden E, et al. The Oslo Balloon An-gioplasty versus Conservative Treatment Study (OBACT)—the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication[J]. Eur J Vasc Endovasc Surg, 2007, 33(1): 3-12.
|
| 26 |
European Stroke Organisation,Tendera M,Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracrani-al carotid and vertebral, mesenteric, renal, upper and lower ex-tremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiolo-gy (ESC) [J]. Eur Heart J, 2011, 32(22): 2851-2906.
|
| 27 |
Pande RL,Hiatt WR,Zhang P, et al. A pooled analysis of the du-rability and predictors of treatment response of cilostazol in pa-tients with intermittent claudication[J]. Vasc Med, 2010, 15(3): 181-188.
|
| 28 |
Momsen AH,Jensen MB,Norager CB, et al. Drug therapy for im-proving walking distance in intermittent claudication: a systemat-ic review and meta-analysis of robust randomised controlled stud-ies[J]. Eur J Vasc Endovasc Surg, 2009, 38(4): 463-474.
|
| 29 |
O'Donnell ME,Badger SA,Sharif MA, et al. The vascular and biochemical effects of cilostazol in patients with peripheral arteri-al disease[J]. J Vasc Surg, 2009, 49(5): 1226-1234.
|
| 30 |
Spronk S,Bosch JL,den Hoed PT, et al. Intermittent claudica-tion: clinical effectiveness of endovascular revascularization ver-sus supervised hospital-based exercise training--randomized controlled trial[J]. Radiology, 2009, 250(2): 586-595.
|
| 31 |
Bradbury AW,Adam DJ,Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival predic-tion model to facilitate clinical decision making[J]. J Vasc Surg, 2010, 5195 Suppl): 52S-68S.
|
| 32 |
Adam DJ,Beard JD,Cleveland T, et al. Bypass versus angioplas-ty in severe ischaemia of the leg (BASIL): multicentre, ran-domised controlled trial[J]. Lancet, 2005, 366(9501): 1925-1934.
|
| 33 |
Tetteroo E,van der Graaf Y,Bosch JL, et al. Randomised com-parison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group[J]. Lancet, 1998, 351(9110): 1153-1159.
|
| 34 |
Schillinger M,Sabeti S,Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting[J]. Circulation, 2007, 115(21): 2745-2749.
|
| 35 |
Dick P,Wallner H,Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial fem-oral artery lesions[J]. Catheter Cardiovasc Interv, 2009, 74(7): 1090-1095.
|
| 36 |
Laird JR,Katzen BT,Scheinert D, et al. Nitinol stent implanta-tion versus balloon angioplasty for lesions in the superficial femo-ral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial[J]. Circ Cardiovasc Interv, 2010, 3(3): 267-276.
|
| 37 |
Hirsch AT,Haskal ZJ,Hertzer NR, et al. ACC/AHA 2005 guide-lines for the management of patients with peripheral arterial dis-ease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American As-sociation for Vascular Surgery/Society for Vascular Surgery, Soci-ety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiolo-gy, and the ACC/AHA Task Force on Practice Guidelines (Writ-ing Committee to Develop Guidelines for the Management of Pa-tients With Peripheral Arterial Disease) endorsed by the Ameri-can Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation[J]. J Am Coll Cardiol, 2006, 47(6): 1239-1312.
|
| 38 |
Brogneaux C,Sprynger M,Magnee M, et al. 2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases[J]. Rev Med Liege, 2012, 67(11): 560-565.
|
| 39 |
Tepe G,Zeller T,Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg[J]. N Engl J Med, 2008, 358(7): 689-699.
|
| 40 |
Ferraresi R,Centola M,Ferlini M, et al. Long-term outcomes af-ter angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia[J]. Eur J Vasc Endovasc Surg, 2009, 37(3): 336-342.
|
| 41 |
Conrad MF,Kang J,Cambria RP, et al. Infrapopliteal balloon an-gioplasty for the treatment of chronic occlusive disease[J]. J Vasc Surg, 2009, 50(4): 799-805.
|
| 42 |
Siablis D,Karnabatidis D,Katsanos K, et al. Infrapopliteal appli-cation of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome[J]. J Vasc Interv Radiol, 2009, 20(9): 1141-1150.
|
| 43 |
Olsen PS,Gustafsen J,Rasmussen L, et al. Long-term results af-ter arterial surgery for arteriosclerosis of the lower limbs in young adults[J]. Eur J Vasc Surg, 1988, 2(1): 15-18.
|
| 44 |
Reed AB,Conte MS,Donaldson MC, et al. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting[J]. J Vasc Surg, 2003, 37(6): 1219-1225.
|
| 45 |
Eagle KA,Berger PB,Calkins H, et al. ACC/AHA guideline up-date for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Periop-erative Cardiovascular Evaluation for Noncardiac Surgery) [J]. Circulation, 2002, 105(10): 1257-1267.
|
| 46 |
Twine CP,McLain AD. Graft type for femoro-popliteal bypass surgery[J]. Cochrane Database Syst Rev, 2010: CD001487.
|
| 47 |
Chiu KW,Davies RS,Nightingale PG, et al. Review of direct ana-tomical open surgical management of atherosclerotic aorto-iliac occlusive disease[J]. Eur J Vasc Endovasc Surg, 2010, 39(4): 460-471.
|
| 48 |
Rooke TW,Hirsch AT,Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with pe-ripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in col-laboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery[J]. Catheter Cardiovasc Interv, 2012, 79(4): 501-531.
|
| 49 |
Griffiths GD,Nagy J,Black D, et al. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytet-rafluoroethylene bypass grafting[J]. Br J Surg, 2004, 91(5): 560-562.
|
| 50 |
SCAMICOS. PTFE bypass to below-knee arteries: distal vein col-lar or not? A prospective randomised multicentre study[J]. Eur J Vasc Endovasc Surg, 2010, 39(6): 747-754.
|
| 51 |
Johnson WC,Lee KK. A comparative evaluation of polytetrafluo-roethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study[J]. J Vasc Surg, 2000, 32(2): 268-277.
|
| 52 |
Brumberg RS,Back MR,Armstrong PA, et al. The relative impor-tance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure[J]. J Vasc Surg, 2007, 46(6): 1160-1166.
|
| 53 |
Bandyk DF. Surveillance after lower extremity arterial bypass[J]. Perspect Vasc Surg Endovasc Ther, 2007, 19(4): 376-383.
|
| 54 |
Davies AH,Hawdon AJ,Sydes MR, et al. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST) [J]. Circula-tion, 2005, 112(13): 1985-1991.
|
| 55 |
Brown J,Lethaby A,Maxwell H, et al. Antiplatelet agents for pre-venting thrombosis after peripheral arterial bypass surgery[J]. Co-chrane Database Syst Rev, 2008: CD000535.
|
| 56 |
Anand SS. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral antico-agulants or Aspirin study) [J]. Lancet, 2000, 355(9201): 346-351.
|
| 57 |
Johnson WC,Williford WO, Department of Veterans Affairs Co-operative Study. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to pa-tients with peripheral arterial bypass procedures: a prospective randomized study[J]. J Vasc Surg, 2002, 35(3): 413-421.
|
| 58 |
Dick F,Diehm N,Galimanis A, et al.Surgical or endovascular re-vascularization in patients with critical limb ischemia: influence of diabetes mellitus on clinical outcome[J]. J Vasc Surg, 2007, 45(4): 751-761.
|
| 59 |
Wolfe JH,Wyatt MG. Critical and subcritical ischaemia[J]. Eur J Vasc Endovasc Surg, 1997, 13(6): 578-582.
|
| 60 |
Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions[J]. J Vasc Surg, 2007, 45(4): 645-654.
|
| 61 |
Norgren L,Hiatt WR,Dormandy JA, et al. Inter-Society Consen-sus for the Management of Peripheral Arterial Disease (TASC II) [J]. J Vasc Surg, 2007, 45(Suppl S): S5-S67.
|
| 62 |
Mamode N,Scott RN. Graft type for femoro-popliteal bypass sur-gery[J]. Cochrane Database Syst Rev, 2000: CD001487.
|
| 63 |
Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M,Born G, et al. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial[J]. J Intern Med, 2007, 261(3): 276-284.
|
| 64 |
Dormandy JA. Prostanoid drug therapy for peripheral arterial oc-clusive disease—the European experience[J]. Vasc Med, 1996, 1(2): 155-158.
|
| 65 |
Creutzig A,Lehmacher W,Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlu-sive disease stages III and IV[J]. Vasa, 2004, 33(3): 137-144.
|
| 66 |
Bradbury AW, BASIL trial Investigators and Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial in perspective[J]. J Vasc Surg, 2010, 51(5 Suppl): 1S-4S.
|
| 67 |
Green RM,Abbott WM,Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a ran-domized trial[J]. J Vasc Surg, 2000, 31(3): 417-425.
|
| 68 |
AbuRahma AF,Robinson PA,Holt SM. Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudi-cant patients with bilateral above knee femoropopliteal bypasses[J]. Surgery, 1999, 126(4): 594-601.
|
| 69 |
Pomposelli FB Jr,Marcaccio EJ,Gibbons GW, et al. Dorsalis pe-dis arterial bypass: durable limb salvage for foot ischemia in pa-tients with diabetes mellitus[J]. J Vasc Surg, 1995, 21(3): 375-384.
|
| 70 |
Archie JPJr. Femoropopliteal bypass with either adequate ipsilat-eral reversed saphenous vein or obligatory polytetrafluoroethylene[J]. Ann Vasc Surg, 1994, 8(5): 475-484.
|
| 71 |
Bernstein EF,Rhodes GA,Stuart SH, et al. Toe pulse reappear-ance time in prediction of aortofemoral bypass success[J]. Ann Surg, 1981, 193(2): 201-205.
|
| 72 |
Hamdan AD,Rayan SS,Hook SC, et al. Bypasses to tibial vessels using polytetrafluoroethylene as the solo conduit in a predomi-nantly diabetic population[J]. Vasc Endovascular Surg, 2002, 36(1): 59-63.
|
| 73 |
Henke PK,Blackburn S,Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft pa-tency, limb salvage, and mortality[J]. J Vasc Surg, 2004, 39(2): 357-365.
|
| 74 |
Diehm N,Schillinger M,Minar E, et al. TASC II section E3 on the treatment of acute limb ischemia: commentary from European interventionists[J]. J Endovasc Ther, 2008, 15(1): 126-128.
|
| 75 |
Sobel M,Verhaeghe R, American College of Chest Physicians, et al. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [J]. Chest, 2008, 133(6 Suppl): 815S-843S.
|
| 76 |
Ouriel K,Shortell CK,DeWeese JA, et al. A comparison of throm-bolytic therapy with operative revascularization in the initial treat-ment of acute peripheral arterial ischemia[J]. J Vasc Surg, 1994, 19(6): 1021-1030.
|
| 77 |
Results of a prospective randomized trial evaluating surgery ver-sus thrombolysis for ischemia of the lower extremity. The STILE trial[J]. Ann Surg, 1994, 220(3): 251-266.
|
| 78 |
Ouriel K,Veith FJ,Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arte-rial occlusion of the legs. Thrombolysis or Peripheral Arterial Sur-gery (TOPAS) Investigators[J]. N Engl J Med, 1998, 338(16): 1105-1111.
|